Skip to Content
Cancer Therapy Evaluation Program (CTEP)
Last Updated: 03/03/16

Jeffrey S. Abrams, MD

Jeffrey S. Abrams, MD

Acting Director for Clinical Research, NCI

Associate Director
Cancer Therapy Evaluation Program
Division of Cancer Treatment and Diagnosis

Dr. Abrams is currently the Acting Director for Clinical Research in the Division of Cancer Treatment and Diagnosis (DCTD) at NCI and also is Associate Director of the Cancer Therapy Evaluation Program (CTEP). After completing his medical oncology fellowship (University of Maryland, 1984), Dr. Abrams joined the University of Maryland faculty from 1985-1992 where he directed their Breast Cancer Evaluation Program and was Associate Professor of Medicine and Oncology. In 1993, he joined NCI and was responsible for managing the breast cancer treatment trials portfolio for the Cancer Therapy Evaluation Program. In 2004, he was appointed Chief of the Clinical Investigations Branch which directs the NCI-supported Clinical Trials Cooperative Group program. In 2008, Dr. Abrams became Associate Director of CTEP, DCTD and in 2010, was named Acting Director for Clinical Research, DCTD. Dr. Abrams is responsible for leading a broad, multidisciplinary clinical research effort to coordinate a nationwide, and international, phase 1-3 clinical trials program testing new treatment approaches for cancer. Dr. Abrams has authored over 95 original publications in the field of breast cancer and clinical trials in general.

About the
Associate Director

Jeffrey Abrams Dr. Abrams is currently the Acting Director for Clinical Research in the Division of Cancer Treatment and Diagnosis (DCTD) at NCI and also is Associate Director of the Cancer Therapy Evaluation Program (CTEP). After completing his medical oncology fellowship (University of Maryland, 1984), Dr. Abrams joined the University of Maryland faculty from 1985-1992 where he directed their Breast Cancer Evaluation Program and was Associate Professor of Medicine and Oncology. In 1993, he joined NCI and was responsible for managing the breast cancer treatment trials portfolio for the Cancer Therapy Evaluation Program. More…